Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 47Rectal Neoplasms 29Stomach Neoplasms 24Colorectal Neoplasms 24Triple Negative Breast Neoplasms 18Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Colonic Neoplasms 10Locally Advanced Rectal Cancer 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Brain Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Pancreatic Neoplasms 4Neoplasms 4Gastrointestinal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroendocrine Tumors 3HER2-positive Breast Cancer 3Cholangiocarcinoma 3Advanced Solid Tumors 3Recurrence 2Neoplasm, Residual 2Meningeal Neoplasms 2Locally Advanced Colorectal Cancer 2Esophageal Squamous Cell Carcinoma 2Early Low Rectal Cancer 2Colorectal Cancer Metastatic 2

Interventions

toripalimab 1potassium oxonate 1gimeracil 1apatinib 1Tegafur 1Nivolumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Malignant Neoplasms of Digestive Organs × Capecitabine × Clear all
NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡